Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Forian Inc. stock logo
FORA
Forian
$2.70
+0.4%
$2.97
$1.85
$4.15
$84.06M1.0325,148 shs8,200 shs
Modular Medical, Inc. stock logo
MODD
Modular Medical
$1.61
+0.5%
$1.75
$0.84
$2.22
$35.26M0.5177,345 shs31,900 shs
Science 37 Holdings, Inc. stock logo
SNCE
Science 37
$5.75
$5.73
$3.73
$12.96
$34.33M0.5543,227 shsN/A
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
$2.91
+0.7%
$3.61
$1.04
$5.24
$33.26M1.8222,335 shs134,300 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Forian Inc. stock logo
FORA
Forian
0.00%-0.74%-7.85%+5.06%+0.75%
Modular Medical, Inc. stock logo
MODD
Modular Medical
0.00%+1.90%+1.26%-0.62%-9.04%
Science 37 Holdings, Inc. stock logo
SNCE
Science 37
0.00%0.00%0.00%+1.23%+1.30%
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
0.00%-0.51%-19.83%+7.38%-5.52%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Forian Inc. stock logo
FORA
Forian
2.3397 of 5 stars
3.52.00.00.01.91.71.3
Modular Medical, Inc. stock logo
MODD
Modular Medical
2.9941 of 5 stars
3.55.00.00.00.63.30.6
Science 37 Holdings, Inc. stock logo
SNCE
Science 37
N/AN/AN/AN/AN/AN/AN/AN/A
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
2.4754 of 5 stars
3.53.00.00.03.40.80.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Forian Inc. stock logo
FORA
Forian
3.00
Buy$7.67183.95% Upside
Modular Medical, Inc. stock logo
MODD
Modular Medical
3.00
Buy$4.25163.98% Upside
Science 37 Holdings, Inc. stock logo
SNCE
Science 37
2.00
HoldN/AN/A
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
3.00
Buy$26.50810.65% Upside

Current Analyst Ratings

Latest SNCE, FORA, TARA, and MODD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/22/2024
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$26.00 ➝ $30.00
4/8/2024
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$23.00
4/4/2024
Forian Inc. stock logo
FORA
Forian
Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
3/21/2024
Modular Medical, Inc. stock logo
MODD
Modular Medical
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSpeculative Buy ➝ Speculative Buy$5.00
3/14/2024
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$23.00
(Data available from 5/6/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Forian Inc. stock logo
FORA
Forian
$20.48M4.10N/AN/AN/A
Modular Medical, Inc. stock logo
MODD
Modular Medical
N/AN/AN/AN/A$0.46 per shareN/A
Science 37 Holdings, Inc. stock logo
SNCE
Science 37
$60.26M0.57N/AN/A$16.70 per share0.34
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
N/AN/AN/AN/A$6.01 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Forian Inc. stock logo
FORA
Forian
N/A$0.338.18N/AN/AN/AN/A5/10/2024 (Estimated)
Modular Medical, Inc. stock logo
MODD
Modular Medical
-$13.88M-$0.97N/AN/AN/AN/A-235.93%-180.37%6/24/2024 (Estimated)
Science 37 Holdings, Inc. stock logo
SNCE
Science 37
-$50.99M-$21.40N/AN/A-206.86%-83.09%-61.58%N/A
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
-$40.42M-$3.74N/AN/AN/AN/A-58.80%-51.37%8/1/2024 (Estimated)

Latest SNCE, FORA, TARA, and MODD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/28/2024Q4 2023
Forian Inc. stock logo
FORA
Forian
N/A-$0.01-$0.01-$0.06$5.72 million$5.37 million
3/13/2024Q4 2023
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
-$1.03-$0.90+$0.13-$0.90N/AN/A
2/13/2024Q3 2024
Modular Medical, Inc. stock logo
MODD
Modular Medical
-$0.17-$0.23-$0.06-$0.23N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Forian Inc. stock logo
FORA
Forian
N/AN/AN/AN/AN/A
Modular Medical, Inc. stock logo
MODD
Modular Medical
N/AN/AN/AN/AN/A
Science 37 Holdings, Inc. stock logo
SNCE
Science 37
N/AN/AN/AN/AN/A
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Forian Inc. stock logo
FORA
Forian
N/AN/AN/A
Modular Medical, Inc. stock logo
MODD
Modular Medical
N/A
1.63
1.63
Science 37 Holdings, Inc. stock logo
SNCE
Science 37
N/A
4.17
4.17
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
N/A
10.53
10.53

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Forian Inc. stock logo
FORA
Forian
19.25%
Modular Medical, Inc. stock logo
MODD
Modular Medical
27.47%
Science 37 Holdings, Inc. stock logo
SNCE
Science 37
40.67%
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
38.13%

Insider Ownership

CompanyInsider Ownership
Forian Inc. stock logo
FORA
Forian
31.30%
Modular Medical, Inc. stock logo
MODD
Modular Medical
32.34%
Science 37 Holdings, Inc. stock logo
SNCE
Science 37
6.80%
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
18.40%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Forian Inc. stock logo
FORA
Forian
10231.13 millionN/AOptionable
Modular Medical, Inc. stock logo
MODD
Modular Medical
3721.90 million14.82 millionNot Optionable
Science 37 Holdings, Inc. stock logo
SNCE
Science 37
4605.97 million5.56 millionNot Optionable
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
2611.43 million9.33 millionOptionable

SNCE, FORA, TARA, and MODD Headlines

SourceHeadline
TARA Stock Earnings: Protara Therapeutics Misses EPS for Q1 2024TARA Stock Earnings: Protara Therapeutics Misses EPS for Q1 2024
investorplace.com - May 2 at 1:06 PM
Protara Therapeutics: Q1 Earnings SnapshotProtara Therapeutics: Q1 Earnings Snapshot
sfgate.com - May 2 at 8:35 AM
Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business UpdateProtara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update
globenewswire.com - May 2 at 8:00 AM
Protara Therapeutics (TARA) Price Target Decreased by 11.76% to 27.54Protara Therapeutics (TARA) Price Target Decreased by 11.76% to 27.54
msn.com - April 17 at 12:11 PM
Protara Therapeutics, Inc. (TARA)Protara Therapeutics, Inc. (TARA)
finance.yahoo.com - April 15 at 6:45 PM
Heres Why Protara Therapeutics (TARA) Is a Great Buy the Bottom Stock NowHere's Why Protara Therapeutics (TARA) Is a Great 'Buy the Bottom' Stock Now
zacks.com - April 12 at 10:56 AM
Buy Rating for Protara Therapeutics’ TARA-002 Based on Promising Clinical Data and Market Potential in NMIBC TreatmentBuy Rating for Protara Therapeutics’ TARA-002 Based on Promising Clinical Data and Market Potential in NMIBC Treatment
markets.businessinsider.com - April 9 at 2:25 AM
Protara Therapeutics Shares Interim Data From Bladder Cancer Study, Raises $45M Via EquityProtara Therapeutics Shares Interim Data From Bladder Cancer Study, Raises $45M Via Equity
msn.com - April 5 at 3:10 PM
Protara Reaches Alignment With FDA On A Registrational Path Forward For IV Choline ChlorideProtara Reaches Alignment With FDA On A Registrational Path Forward For IV Choline Chloride
markets.businessinsider.com - April 5 at 10:10 AM
Protara Announces Positive Data From TARA-002 Trial In Bladder Cancer; Stock UpProtara Announces Positive Data From TARA-002 Trial In Bladder Cancer; Stock Up
markets.businessinsider.com - April 5 at 10:10 AM
Protara Therapeutics Announces Oversubscribed $45 Million Private Placement FinancingProtara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing
globenewswire.com - April 5 at 8:04 AM
Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral NutritionProtara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition
globenewswire.com - April 5 at 8:02 AM
Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBCProtara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC
globenewswire.com - April 5 at 8:00 AM
3 Stocks That Could Help You Retire on a Private Island3 Stocks That Could Help You Retire on a Private Island
investorplace.com - March 23 at 6:00 AM
Buy Rating on Protara Therapeutics Backed by Promising TARA-002 Clinical Trials and Significant Market OpportunityBuy Rating on Protara Therapeutics Backed by Promising TARA-002 Clinical Trials and Significant Market Opportunity
markets.businessinsider.com - March 13 at 6:27 PM
Protara Therapeutics: Q4 Earnings SnapshotProtara Therapeutics: Q4 Earnings Snapshot
chron.com - March 13 at 1:26 PM
Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateProtara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
globenewswire.com - March 13 at 8:00 AM
TARA Aug 2024 7.500 callTARA Aug 2024 7.500 call
finance.yahoo.com - March 3 at 11:42 PM
TARA May 2024 2.500 putTARA May 2024 2.500 put
finance.yahoo.com - March 3 at 11:42 PM
Non Muscle Invasive Bladder Cancer Pipeline Outlook Report 2024Non Muscle Invasive Bladder Cancer Pipeline Outlook Report 2024
theglobeandmail.com - February 28 at 7:58 PM
Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care ConferenceProtara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
globenewswire.com - February 28 at 8:00 AM
NorthSea Therapeutics commences Phase IIa trial for IFALD therapyNorthSea Therapeutics commences Phase IIa trial for IFALD therapy
msn.com - February 22 at 7:53 PM
Were Keeping An Eye On Protara Therapeutics (NASDAQ:TARA) Cash Burn RateWe're Keeping An Eye On Protara Therapeutics' (NASDAQ:TARA) Cash Burn Rate
finance.yahoo.com - February 17 at 8:43 AM
CG Oncologys Lead Bladder Cancer Drug Offers A Strong Potential Revenue Stream With Buyout OptionalityCG Oncology's Lead Bladder Cancer Drug Offers A Strong Potential Revenue Stream With Buyout Optionality
seekingalpha.com - January 25 at 3:04 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Forian logo

Forian

NASDAQ:FORA
Forian Inc. provides software and information solutions, proprietary data driven insights, and predictive analytics to optimize and measure the operational, clinical, and financial performance of its life science and healthcare customers. It operates through three segments: Information & Software, Services, and Other. The company's products include BioTrack, a vertically integrated point of sale, manufacturing, delivery, and cultivator software solution for dispensaries, cultivators, manufacturers, and distributors; and Cannalytics, a Software as a Service based analytics solution that provides customers with a presentation of business performance. Its products also comprise BioTrack seed-to-sale compliance traceability platform, which is used to manage the tracking and tracing of various cannabis products from cultivation to sale; and BioTrack State Traceability & Enforcement Monitoring System to ensure transparency and accountability throughout cannabis supply chain. In addition, the company offers security monitoring and web marketing services. Forian Inc. was incorporated in 2020 and is headquartered in Newtown, Pennsylvania. Forian Inc.
Modular Medical logo

Modular Medical

NASDAQ:MODD
Modular Medical, Inc. operates as a development stage medical device company. It focuses on the design, development, and commercialization of insulin pumps. It offers MODD1, a two-part patch pump for diabetes. The company was founded in 1998 and is headquartered in San Diego, California.
Science 37 logo

Science 37

NASDAQ:SNCE
Science 37 Holdings, Inc. engages in patient-centric clinical trial activities in North Carolina. Its platform enables modern and digital approaches to clinical research, including the patient and trial investigators, nurses, coordinators, and sponsors, standardize evidence generation, and harmonize data. The company's platform also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices for orchestrating clinical trials; and extensive configuration to support virtually any phase of clinical study and therapeutic area. In addition, the company licenses its proprietary hosted technology platform to various life science institutions. It serves large and mid-sized pharmaceutical companies, contract research organizations, academic institutions, and biotech companies. Science 37 Holdings, Inc. was founded in 2014 and is based in Research Triangle Park, North Carolina. As of March 11, 2024, Science 37 Holdings, Inc. operates as a subsidiary of eMed, LLC.
Protara Therapeutics logo

Protara Therapeutics

NASDAQ:TARA
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.